AUTH/2224/4/09 - Professor of Cardiology v Merck Sharp & Dohme

Promotion of Cozaar

  • Received
    15 April 2009
  • Case number
    AUTH/2224/4/09
  • Applicable Code year
    2008
  • Completed
    22 May 2009
  • No breach Clause(s)
    2, 3.2, 7.2 and 9.1
  • Additional sanctions
  • Appeal
    No appeal
  • Review
    August 2010

Case Summary

A professor of cardiology complained that a Cozaar (losartan) journal advertisement, issued by Merck Sharp & Dohme and headed ‘Cozaar: The facts’, did not refer to the warning regarding the use of losartan in patients with heart failure who were on a beta-blocker and strongly implied that losartan was widely indicated for patients aged 60 years and over with chronic heart failure where acetylcholine esterase (ACE) inhibitors were unsuitable. The advertisement did not refer to the specific warnings in the summary of product characteristics (SPC) for losartan: ie that ‘The combination of losartan with a beta-blocker should be used with caution’ (Section 4.4) and ‘An increased mortality was observed in ELITE II in the small subgroup (22% of all HF [heart failure] patients) taking beta-blockers at baseline’ (Section 5.1).

The complainant did not consider that prescribers reading the advertisement would be aware of this important caution. This was particularly important given that professional bodies and the Department of Health strongly encouraged increased prescribing of beta-blockers for this patient group.

The complainant considered it highly likely that the advertisement could lead to increased use of losartan specifically in the group for which there was a caution and increase mortality in this patient group. This was irresponsible and should be condemned. The advertisement was not only misleading but dangerous and should be withdrawn before it caused further damage.

The detailed response from Merck Sharp & Dohme is given below.

The Panel noted that the aim of the advertisement was to compare the licensed indications of Cozaar with those of six other All-antagonists (AIIAs). Above a table of data it was claimed that ‘Cozaar is the only AIIA with four indications’.  The table listed one of Cozaar’s indications, not held by any of the other medicines, as ‘Chronic heart failure in patients ≥ 60 years with an LVF ≤ 40% and where ACE inhibitors are unsuitable due to incompatability or contraindication’.  This was a new indication. The Cozaar SPC (Section 4.1) did not qualify the indication in any way or refer the reader to any precautions or warnings about the concomitant use of Cozaar with beta-blockers. The Panel noted that the prescribing information in the advertisement at issue stated, under a heading of heart failure, ‘Use with caution in… combination with a beta-blocker’.

The Panel considered that the advertisement was not inconsistent with the particulars listed in the Cozaar SPC and in that regard no breach of the Code was ruled. The Panel further did not consider that the advertisement was dangerous or misleading as alleged.